Is Entera Bio Stock a Good Investment?

Entera Bio Investment Advice

  ENTX
To provide specific investment advice or recommendations on Entera Bio stock, we recommend investors consider the following general factors when evaluating Entera Bio. This will help you to make an informed decision on whether to include Entera Bio in one of your diversified portfolios:
  • Examine Entera Bio's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
  • Research Entera Bio's leadership team and their track record. Good management can help Entera Bio navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
  • Consider the overall health of the Biotechnology space and any emerging trends that could impact Entera Bio's business and its evolving consumer preferences.
  • Compare Entera Bio's performance and market position to its competitors. Analyze how Entera Bio is positioned in terms of product offerings, innovation, and market share.
  • Check if Entera Bio pays a dividend and its dividend yield and payout ratio.
  • Review what financial analysts are saying about Entera Bio's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Entera Bio stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Entera Bio is a good investment.
 
Sell
 
Buy
Strong Sell
We provide trade advice to complement the prevailing expert consensus on Entera Bio. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time. To make sure Entera Bio is not overpriced, please confirm all Entera Bio fundamentals, including its current ratio, and the relationship between the ebitda and number of employees . Please also check Entera Bio price to earning to verify your buy or sell decision is consistent with all fundamental data available and that the company can sustain itself in the current economic cycle.

Market Performance

Very WeakDetails

Volatility

RiskyDetails

Hype Condition

Over hypedDetails

Current Valuation

UndervaluedDetails

Odds Of Distress

LowDetails

Economic Sensitivity

Almost neglects market trendsDetails

Investor Sentiment

InterestedDetails

Analyst Consensus

BuyDetails

Financial Strenth (F Score)

PoorDetails

Financial Leverage

Not RatedDetails

Reporting Quality (M-Score)

Unlikely ManipulatorDetails

Examine Entera Bio Stock

Researching Entera Bio's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 19.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.26. Entera Bio had not issued any dividends in recent years.
To determine if Entera Bio is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Entera Bio's research are outlined below:
Entera Bio generated a negative expected return over the last 90 days
Entera Bio may become a speculative penny stock
Entera Bio has high historical volatility and very poor performance
The company reported the previous year's revenue of 14 K. Net Loss for the year was (8.89 M) with profit before overhead, payroll, taxes, and interest of 33 K.
Entera Bio currently holds about 17.28 M in cash with (7.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.6.
Entera Bio has a poor financial position based on the latest SEC disclosures
Roughly 19.0% of the company shares are held by company insiders
Entera Bio uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Entera Bio. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Entera Bio's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
29th of March 2024
Upcoming Quarterly Report
View
3rd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
29th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View
Earnings surprises can significantly impact Entera Bio's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Entera Bio's investors have experienced.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-05-10
2024-03-31-0.06-0.050.0116 
2024-03-08
2023-12-31-0.08-0.070.0112 
2023-11-14
2023-09-30-0.09-0.070.0222 
2022-11-10
2022-09-30-0.13-0.110.0215 
2021-11-10
2021-09-30-0.11-0.090.0218 
2024-11-12
2024-09-30-0.05-0.08-0.0360 
2023-05-05
2023-03-31-0.12-0.080.0433 
2022-08-11
2022-06-30-0.16-0.110.0531 

Know Entera Bio's Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Entera Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Entera Bio backward and forwards among themselves. Entera Bio's institutional investor refers to the entity that pools money to purchase Entera Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Hightower Advisors, Llc2024-03-31
0.0
Two Sigma Securities, Llc2024-03-31
0.0
Note, although Entera Bio's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Entera Bio's market capitalization trends

The company currently falls under 'Micro-Cap' category with a current market capitalization of 63.38 M.

Market Cap

16.53 Million

Entera Bio's profitablity analysis

Last ReportedProjected for Next Year
Return On Tangible Assets(0.76)(0.79)
Return On Capital Employed(0.83)(0.87)
Return On Assets(0.76)(0.79)
Return On Equity(0.86)(0.90)
Determining Entera Bio's profitability involves analyzing its financial statements and using various financial metrics to determine if Entera Bio is a good buy. For example, gross profit margin measures Entera Bio's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Entera Bio's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Entera Bio's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Entera Bio. Check Entera Bio's Beneish M Score to see the likelihood of Entera Bio's management manipulating its earnings.

Evaluate Entera Bio's management efficiency

Entera Bio has return on total asset (ROA) of (0.7061) % which means that it has lost $0.7061 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4467) %, meaning that it created substantial loss on money invested by shareholders. Entera Bio's management efficiency ratios could be used to measure how well Entera Bio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.79 in 2024. Return On Capital Employed is likely to drop to -0.87 in 2024. At this time, Entera Bio's Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 14.2 M in 2024, whereas Other Current Assets are likely to drop slightly above 209 K in 2024.
Last ReportedProjected for Next Year
Book Value Per Share 0.36  0.38 
Tangible Book Value Per Share 0.36  0.38 
Enterprise Value Over EBITDA(0.77)(0.81)
Price Book Value Ratio 1.68  1.76 
Enterprise Value Multiple(0.77)(0.81)
Price Fair Value 1.68  1.76 
Enterprise Value6.8 M6.4 M
Understanding the operational decisions made by Entera Bio management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Beta
1.59

Basic technical analysis of Entera Stock

As of the 2nd of December, Entera Bio shows the Downside Deviation of 3.46, mean deviation of 2.92, and Coefficient Of Variation of 5505.25. Entera Bio technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.

Entera Bio's insider trading activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Entera Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Entera Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Entera Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Entera Bio's Outstanding Corporate Bonds

Entera Bio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Entera Bio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Entera bonds can be classified according to their maturity, which is the date when Entera Bio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Understand Entera Bio's technical and predictive indicators

Using predictive indicators to make investment decisions involves analyzing Entera Bio's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.

Consider Entera Bio's intraday indicators

Entera Bio intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Entera Bio stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Entera Bio time-series forecasting models is one of many Entera Bio's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Entera Bio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Entera Stock media impact

Far too much social signal, news, headlines, and media speculation about Entera Bio that are available to investors today. That information is available publicly through Entera media outlets and privately through word of mouth or via Entera internal channels. However, regardless of the origin, that massive amount of Entera data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Entera Bio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Entera Bio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Entera Bio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Entera Bio alpha.

Entera Bio Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Entera Bio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Entera Bio Corporate Management

Hillel MBAChief OfficerProfile
Miranda MBACEO DirectorProfile
II MDChief OfficerProfile
Gregory BurshteinChief DevelopmentProfile
Dana CPAChief OfficerProfile

Additional Tools for Entera Stock Analysis

When running Entera Bio's price analysis, check to measure Entera Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entera Bio is operating at the current time. Most of Entera Bio's value examination focuses on studying past and present price action to predict the probability of Entera Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Entera Bio's price. Additionally, you may evaluate how the addition of Entera Bio to your portfolios can decrease your overall portfolio volatility.